AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06428656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbiotics supplementation
Description: The participants will consume one capsule of postbiotics supplement per day
Study NCT06428656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: The participants will consume one capsule of placebo per day
Study NCT05749237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiratory exercises
Description: respiratory exercises
Study NCT05749237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: relaxation exercises
Description: relaxation exercises
Study NCT05749237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: relaxation exercises
Description: relaxation exercises
Study NCT05751733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect of anti-C-Kit and PDGFR.
Study NCT05751733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
Description: Second-line TKI drugs
Study NCT05073393 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sugar stress
Description: Sucrose rinsing for 14 days (8-10 times a day) followed by 14 days without sucrose rinsing
Study NCT05073393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar stress
Description: Sucrose rinsing for 14 days (8-10 times a day) followed by 14 days without sucrose rinsing
Study NCT04844658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NASAFYTOL®
Description: Dietary supplement presented as green soft gel capsules of 1008 mg, containing a bioactive mixture of turmeric extract or curcumin, natural quercetin from Sophora japonica L. and vitamin D3.
Study NCT04844658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FULTIUM® -D3 800
Description: Vitamin D , FULTIUM® - D3 800 is a blue soft capsule that contains 800 UI (20 µg) of D3 vitamin (cholecalciferol).
Study NCT04844658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strandard of care treatment
Description: Strandard of care treatment for Covid-19 infection
Study NCT04844658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strandard of care treatment
Description: Strandard of care treatment for Covid-19 infection
Study NCT06185634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention - Pasta at dinner
Description: The pasta at dinner nutritional intervention will consist, as the name suggests, in eating pasta at dinner for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner.
Study NCT06185634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention - Pasta at lunch
Description: The pasta at lunch nutritional intervention will consist, as the name suggests, in eating pasta at lunch for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner.
Study NCT04879849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion.
Study NCT04879849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-676
Description: IV infusion.
Study NCT04879849 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided radiation therapy
Description: Radiation therapy.
Study NCT06180330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic baby class
Description: The intervention will consist of exercises for infants. They will be in the water together with parents
Study NCT04843774 — intervention group
Intervention type: DRUG
Intervention: SARS-COV-2 mRNA Vaccine
Description: Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus will be given as standard of care (SOC)
Study NCT05175417 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: 3 tesla (T) MRI to provide higher resolution and quality brain images.
Study NCT06452901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progression and structured surgical training.
Description: Participants will be exposed to different amounts of open vascular surgical training, but only group I will receive the complete structured and progressive training program. This ensures that all participants have access to the potential benefits derived from the intervention. Current evidence supports this approach, which supports the benefits of medical simulation in the training process of surgical residents.
Study NCT06452901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progression and structured surgical training.
Description: Participants will be exposed to different amounts of open vascular surgical training, but only group I will receive the complete structured and progressive training program. This ensures that all participants have access to the potential benefits derived from the intervention. Current evidence supports this approach, which supports the benefits of medical simulation in the training process of surgical residents.
Study NCT05729126 — intervention group
Intervention type: OTHER
Intervention: Questionnare
Description: A questionnaire form is emailed to radiologists to get their response of their practice with hemodialysis and chronic kidney disease patients
Study NCT04011163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VPIA pump
Description: The pump is a specially designed and manufactured infusion syringe pump for intravenous analgesia. It incorporates the VPIA study regimen to meet the specific requirements of the clinical trial. It is intended to be used only for delivering drugs intravenously.
Study NCT05245838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg
Study NCT05245838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg with aluminum hydroxide (alum)
Study NCT05245838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg
Study NCT05245838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Z-1018
Description: contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg, with aluminum hydroxide (alum)
Study NCT04011163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Intravenous medication used is morphine diluted in normal saline to a concentration of 1mg/ml. This is a standard dilution and are routine drugs used as standard of care.
Study NCT06378398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Two 20 mg/day omeprazole tablets taken before the first meal each day for 25-45 days.
Study NCT05245838 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: a suspension for injection supplied as a single-dose vial of 50 mcg varicella zoster virus (VZV) glycoprotein E (gE) antigen and AS01B adjuvant
Study NCT06378398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Two 81 mg/day aspirin tablets taken before the first meal each day for 25-45 days.
Study NCT05942625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10390 tablet
Description: Oral administration of specified dose of HS-10390
Study NCT05942625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Oral administration of matching dose ofplacebo
Study NCT04691154 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: L606 inhalation suspension
Description: L606 inhalation suspension, twice daily dosing
Study NCT05748184 — intervention group
Intervention type: DEVICE
Intervention: ULDCT PACS prototype
Description: The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images.
Study NCT05643768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training (IMST)
Description: 30 breaths/day, 5 days/week, 6 weeks
Study NCT05643768 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle strength training (IMST)
Description: 30 breaths/day, 5 days/week, 6 weeks
Study NCT05195827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRM-125
Description: Antihypertensive
Study NCT06540209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Description: Children will be give Bacillus clausii for 5 days
Study NCT06540209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: Children will be give Saccharomyces boulardii for 5 days
Study NCT06540209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc will be given to all children for 5 days
Study NCT06540209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORS
Description: ORS will be given to all children for 5 days
Study NCT05502900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: White round tablets, each with a dose of 5 mg Melatonin. 4 tablets taken simultaneously at night. Tablets can be crushed and/or taken with a glass of water if the patient wish.
Study NCT06420843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FOODMAP
Description: Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) have been recently investigated in the management of functional gut symptoms in IBS.
Study NCT06420843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FOODMAP
Description: Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) have been recently investigated in the management of functional gut symptoms in IBS.
Study NCT04823039 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample taken
Description: For patients with sepsis who require vaccination during hospitalization, we will analyze the immunogenicity of pneumococcal conjugate vaccine (PCV13) by taking blood samples
Study NCT06105151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119(SAD)
Description: VV119 0.2 mg Group: 2 subjects will receive VV119 0.2 mg, orally; VV119 0.5 mg Group: 6 subjects will receive VV119 0.5 mg, orally; VV119 1 mg Group: 6 subjects will receive VV119 1 mg, orally; VV119 2 mg Group: 6 subjects will receive VV119 2 mg, orally; VV119 3 mg Group:6 subjects will receive VV119 3 mg, orally; VV119 4.5 mg Group:6 subjects will receive VV119 4.5 mg, orally; VV119 6 mg Group:6 subjects will receive VV119 6 mg, orally; VV119 8 mg Group:6 subjects will receive VV119 8 mg, orally; VV119 10 mg Group:6 subjects will receive VV119 10 mg, orally;
Study NCT06105151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119 Placebo(SAD)
Description: VV119 0.5 mg Group: 2 subjects will receive VV119 Placebo 0.5 mg, orally; VV119 1 mg Group: 2 subjects will receive VV119 Placebo 1 mg, orally; VV119 2 mg Group: 2 subjects will receive VV119 Placebo 2 mg, orally; VV119 3 mg Group:2 subjects will receive VV119 Placebo 3 mg, orally; VV119 4.5 mg Group:2 subjects will receive VV119 Placebo 4.5 mg, orally; VV119 6 mg Group:2 subjects will receive VV119 Placebo 6 mg, orally; VV119 8 mg Group:2 subjects will receive VV119 Placebo 8 mg, orally; VV119 10 mg Group:2 subjects will receive VV119 Placebo 10 mg, orally;
Study NCT06105151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119(FE)
Description: A：4 mg VV119, following an overnight fast of at least 10 hours for Period 1; 4mg VV119, administered 30 minutes after the start of a standard meal for Period 2; 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 3; B: 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 1; 4 mg VV119, following an overnight fast of at least 10 hours for Period 2; 4mg VV119, administered 30 minutes after the start of a standard meal for Period 3; C: 4mg VV119, administered 30 minutes after the start of a standard meal for Period 1; 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 2;4 mg VV119, following an overnight fast of at least 10 hours for Period 3.
Study NCT06101667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical management
Description: Best medical management included assessment of vital signs and neurological deficits,airway protection respiratory support,circulation;blood pressure monitoring;nutritional support;complication control;symptomatic treatment;laboratory and imaging examinations;etiological analysis and evaluation; anti platelet（e.g. aspirin,adenosine diphosphate (ADP) receptor inhibitors,Adenosine reuptake inhibitors,Glycoprotein platelet inhibitors）；anticoagulation(e.g. warfarin, rivaroxaban,dabigatran,apixaban,edoxaban)；lipid lowering(e.g. Statins,Fibrates）；control of blood pressure(e.g. Thiazide diuretics,Potassium-sparing,Loop diuretic,Beta-blockers,Angiotensin II receptor blockers,Calcium channel blockers,Alpha blockers,Central alpha-2 receptor agonists);control of blood glucose(e.g. SULFONYLUREAS (SFUs),GLINIDES,BIGUANIDES,ALPHA-GLUCOSIDASE INHIBITORS: STARCH BLOCKERS,THIAZOLIDINEDIONES,GLP-1 ANALOGS,DPP-4 INHIBITORS,SGLT2 inhibitors); control of other risk factors
Study NCT06101667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Description: The strategies that were used for endovascular treatment included :stent retrievers (e.g., Solitaire® \[Medtronic, USA\], Trevo® \[Stryker, USA\], EMBOTRAP® \[Johnson \& Johnson, USA\], Captor® \[HeartCare, China\] and other stent-retriever systems) thromboaspiration (e.g., Penumbra® \[Penumbra, USA\], Afentta® \[HeMo, China\] and other aspiration systems)) balloon angioplasty (e.g., Gateway® \[Stryker, USA\], Neuro RX® \[SinoMed, China\], FocuStar® \[HeMo, China\] and other intracranial balloon catheter systems) stent deployment (e.g., Wingspan® \[Stryker, USA\], Apollo® \[MircoPort, China\], Enterprise® \[Johnson \& Johnson, USA\], Neuroform EZ® \[Stryker, USA\] and other Intracranial stent systems)) intraarterial thrombolysis (with alteplase or urokinase) combinations of above approaches that were left to the discretion of the treating team
Study NCT04275791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triage
Description: Experimental : Trauma patient orientation in a structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
Study NCT05634460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: potassium hydroxide
Description: Potassium hydroxide (KOH) is a topical treatment for Molluscum contagiosum. Dermatologists routinely use potassium hydroxide (KOH) in varying concentrations to identify fungal elements. Because it is a strong alkali with keratolytic characteristics, variable concentrations given for management of MC.
Study NCT05098860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Educational training program includes active stretching, strengthening, and stabilization exercises of head and neck muscles as well as relaxation and breathing exercises.
Study NCT05098860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy Combined with Home Exercise Program
Description: Manual Therapy program includes soft tissue and joint mobilizations of the cervical vertebrae, scapula and thoracic vertebrae.
Study NCT05098860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tele-rehabilitation Assisted Program
Description: Tele-rehabilitation assisted program will be given in the on-line environment. Patients will apply active cervical and thoracic region mobilizations called self-mobilization.
Study NCT06096220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enucleation
Description: Enucleation is complete removal of the cyst from the bony defect of the jaw affected by the lesion. Osteotomy is performed to allow access to the cyst, cystic wall is detached from the bone and removed completely.
Study NCT06096220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enucleation
Description: Enucleation is complete removal of the cyst from the bony defect of the jaw affected by the lesion. Osteotomy is performed to allow access to the cyst, cystic wall is detached from the bone and removed completely.
Study NCT06096220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: incisional biopsy
Description: Lesions clinically abd radiographically consistent with OKC will be submitted for histological examination to confirm the diagnosis of OKC
Study NCT06096220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: incisional biopsy
Description: Lesions clinically abd radiographically consistent with OKC will be submitted for histological examination to confirm the diagnosis of OKC
Study NCT06096220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Application of 5-fluorouracil
Description: 5% 5-fluorouracil cream will be applied immediately after the enucleation to the cystic cavity for 24 hours
Study NCT06096220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Application of Carnoy solution
Description: Carnoy solution will be applied during the enucleation as described previously
Study NCT04790760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement Consumption
Description: Participants will consume one 500 mg cinnamon capsule and one 300 mg aloe vera capsule twice per day for weeks 3-6.
Study NCT04790760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitors
Description: Participants will wear a CGM on the back of their left and right arm for weeks 1-6.
Study NCT05303207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: YOUR SUPER Detox Bundle
Description: During days 1-5, participants will complete the 5-day Your Super Detox, consuming 2 smoothies daily (breakfast and dinner) containing Your Super Detox superfood powders.
Study NCT04534907 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: The combination of exposure and response prevention (ERP) and VR
Description: The combination of exposure and response prevention (ERP) and VR aimed to investigate the combination of an immersive virtual reality environment (VRE) alongside therapist delivered CBT to reduce anxiety when the OCD patients were induced by virtual scene.Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get VR+ERP session twice a week. From the fourth week to the seventh week, patients weill get VR+ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
Study NCT04534907 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional ERP
Description: Patients will achieve the exposure based CBT for total 10 times excluding 8 sessions of ERP. Structured protocol described by Foa et al., 2012. Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get ERP session twice a week. From the fourth week to the seventh week, patients weill get ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
Study NCT06394752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Saline Infusion
Description: Visual Saline Infusion (VSI) is a new intrauterine imaging procedure to identify uterine pathology. The VSI device is a 2.7mm, steerable tip catheter with a camera and illumination at the distal end. The device is intended to evaluate the intrauterine space in an office based, outpatient setting using minimal volume of fluid (3-5cc's).
Study NCT06394752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrosonography
Description: Hydrosonography is an ultrasound based intrauterine imaging technique with sensitivity and specificity ranging from 90% to 100% for identifying uterine pathology. It is performed by inserting a slim 2 mm catheter into the uterine cavity and infusing saline solution to expand the uterus and using abdominal ultrasound to visualize the uterus.
Study NCT06608394 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention